Overview

Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants

Status:
Recruiting

Trial end date:
2023-05-08

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to evaluate the effect of carbamazepine, a strong CYP3A4 inducer, on the steady-state pharmacokinetics (PK) of tavapadon in healthy adult participants.

Phase:

Phase 1

Details

Lead Sponsor:

Cerevel Therapeutics, LLC

Treatments:

Carbamazepine